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Abstract
Over the last decade mouse models of experimental asthma proved to be a valuable tool for the
investigation of mechanisms that underlie acute allergic airway inflammation and development of
airway hyperresponsiveness, two of the hallmarks of human asthma. Nevertheless, these acute
models fail to reflect the aspects of this chronic disease because they do not represent any signs of
chronicity and airway remodelling as it is defined by subepithelial fibrosis, goblet cell hyperplasia
and airway smooth muscle cell hypertrophy. Recent mouse models were successful in overcoming
these limitations by using chronic allergen-challenges. These new models of chronic experimental
asthma now proved as a novel tool to examine the complex interaction of infiltrating inflammatory
cells and structural cells such as fibroblasts and smooth muscle cells that ultimately leads to airway
remodelling and stable airflow limitation. Recent studies clearly demonstrated that T helper 2
(TH2) cells and their typical cytokines play a critical role not only in airway inflammation but also
in the development of airway remodelling. Since the transcription factor GATA-3 is essential for
TH2 cell development and the production of several TH2 type cytokines this intracellular molecule
represents a new promising target for therapeutic intervention in asthma that might even effect
airway remodelling.
Overview
Allergic bronchial asthma is a chronic inflammatory dis-
ease of the airways that is characterized by allergic airway
inflammation and development of airway hyperrespon-
siveness (AHR). Another hallmark of asthma involves var-
ious structural changes of the airway wall such as airway
fibrosis and smooth muscle cell hyperplasia summarized
as airway remodelling [1]. Over the last 15 years animal
models, especially mouse models, of experimental
asthma have been intensively used to investigate the
immuno-pathological mechanisms that ultimately lead to
the formation of this disease. Mostly, these models uti-
lized systemic sensitization to foreign proteins such as
ovalbumin (OVA) adsorbed to the adjuvant aluminium
hydroxide (alum) to induce a T-helper-2 (TH2) cell trig-
gered immune-response together with marked produc-
tion of OVA-specific IgE. Once sensitized, these animals
developed airway eosinophilia and AHR after inhalation
or intra-nasal application of OVA aerosols or OVA-solu-
tions [2]. Such models provided insight into the immuno-
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logical mechanisms of acute allergic inflammation,
helped to identify key cytokines such as interleukin 4 (IL-
4), IL-5 and IL-13 that play critical roles in the regulation
of the local inflammatory process [3] and proofed valua-
ble to investigate the neuro-immunological dysregulation
underlying the development of AHR [4].
Mouse models of chronic experimental asthma
However, since allergic airway inflammation in these
models is induced by short term exposure to the aero-
solized allergen and, therefore, does not persist for longer
than 10 days, these models are limited regarding the mod-
elling of the chronic aspects of asthma, more precisely air-
way remodelling and its patho-physiological
consequences that might result in stable airflow limita-
tion. Furthermore, pathological aspects of experimental
asthma in these acute models are reduced to the central
airways. Since asthma, allergic inflammation and airway
remodelling is observed in peripheral airways of asth-
matic patients as well [5,6] and structural changes espe-
cially of distal airways play a critical role in the
development of irreversible airflow limitation [7] these
aspects represent important hallmarks for disease model-
ling in animals.
Over the last few years airway remodelling became a field
of special interest in asthma research since it is largely
resistant to medication [8] and is an important factor to
develop irreversible airflow limitation, resulting in
progress of asthma severity [9]. To overcome these limita-
tions recently many advanced models have been estab-
lished. Most of these models use systemic sensitization to
ovalbumin (OVA) adsorbed to aluminium hydroxide
(alum) followed by repeated exposure to aerosolized OVA
for 4-8 weeks [10-13]. Within these models it is interest-
ing to note that similar results are achieved with a huge
variety of OVA-aerosol concentrations (0.1 – 2.5%) as
well as the frequency of allergen challenges (2–7 times a
week).
However, the modelling of these chronic aspects of
asthma in animals requires clear definition of airway
remodelling. The pathological analysis on bronchial spec-
imens of asthmatic patients revealed goblet cell hyperpla-
sia of the airway epithelium, hyperplasia of the
submucosal glands, thickening of the epithelial basement
membrane, extracellular matrix deposition in the subepi-
thelial layer and hypertrophy and hyperplasia of the bron-
chial smooth muscle cells [14]. To reflect these hallmarks
of airway remodelling, we sensitized BALB/c mice to OVA
by three intra-peritoneal (i.p.) injection of OVA adsorbed
to alum followed by a twelve week long OVA challenge
period with two challenges a week on consecutive days
[15]. These animals developed chronic allergic inflamma-
tion that in contrast to other models affected the entire
bronchial tree and even persisted after six weeks of OVA
challenge discontinuation. This chronic airway inflamma-
tion was further associated with persistent AHR and stable
airflow limitation as indicated by reduction of baseline
midexpiratory airflow (EF50). In contrast to other models
of chronic experimental asthma, proximal as well as distal
airways revealed marked deposition of collagen fibres in
the airway wall especially in the lamina propria. The air-
way wall was additionally thickened by appearance of
myofibrocytes and enlargement of the airway smooth
muscle layer indicating airway smooth muscle hypertro-
phy. Goblet cell hyperplasia could be observed in all sec-
tions of the bronchial tree. Since this model reflects
human airway remodelling to a high degree it could be
useful for the investigation of the mechanisms that under-
lie this special issue of human asthma.
Lymphocytes and eosinophils in airway 
remodelling
The actual concept of asthma pathogenesis begins with
the differentiation of naïve allergen-specific T-helper cells
towards TH2 cells that are characterized by the expression
of the transcription factor GATA-3 and production of sev-
eral typical cytokines such as IL-5 that controls the activity
and the survival of eosinophils. These cells represent the
main effector cell type of the allergic airway inflammation
and produce a variety of cytotoxic mediators and cationic
proteins such as major basic protein (MBP) and eosi-
nophil cationic protein (ECP) that ultimately lead to epi-
thelial damage [16]. This further triggers several
mechanisms focussing on the reconstitution of the epithe-
lial integrity. One of the main mediators involved in this
process is transforming growth factor-beta (TGF-β) that is
produced by eosinophils and structural cells such as bron-
chial epithelial cells and smooth muscle cells [17]. This
cytokine on the one hand possesses anti-inflammatory
properties that help to limit the inflammatory process in
the airways. On the other hand it triggers airway remodel-
ling since it induces pro-collagen production in fibrob-
lasts and transformation of these cells into smooth muscle
actin containing myofibroblasts [18,19].
We utilized our model of chronic experimental asthma to
assess the effect of a novel therapeutic strategy that targets
eosinophils on airway remodelling and lung function.
Since the infiltration of these cells into the airways
depends on interaction of the C-C chemokine receptor-3
(CCR-3) and its ligands from the eotaxin family, we antag-
onized this chemokine receptor by using a low molecular
weight compound [20]. To mimic the human situation as
closely as possible treatment with the CCR-3 antagonist
started not until allergic airway inflammation has already
been established, but no signs of airway remodelling
could be observed. Systemic application of 30mg/kg body
weight reduced the infiltration of eosinophils into theJournal of Occupational Medicine and Toxicology 2008, 3(Suppl 1):S4 http://www.occup-med.com/content/3/S1/S4
Page 3 of 5
(page number not for citation purposes)
broncho-alveolar lumen and into the airway tissue by
about 70%, whereas infiltration of other inflammatory
cells was not effected significantly. Additionally, neither
subepithelial fibrosis nor hyperplasia of smooth muscle
cells or goblet cells could be observed in animals treated
with the CCR-3 antagonist. Although airway eosinophilia
could not be reduced entirely airway reactivity to meta-
choline was nearly normalized in these animals indicating
that eosinophils play an important, but not an exclusive
role in the processes leading to airway remodelling and
AHR. Both, involvement of eosinophils in development
of AHR and in development of airway remodelling
remain issues of special interest and are discussed highly
controversial. In models of acute experimental asthma
development of AHR is usually accompanied by airway
eosinophilia. Nevertheless, a substantial number of stud-
ies clearly demonstrate that factors other than airway eosi-
nophilia are essential for the development of AHR. These
factors involve TH2-type cytokines such as IL-4 and IL-13
as well as signalling via the Fc-epsilon receptor [21-23].
Furthermore, Tournoy et al. report about a model of acute
experimental asthma where airway eosinophilia and
development of AHR seem to be disconnected [24]. Simi-
lar results were achieved by Siegle et al in a mouse model
of chronic experimental asthma [25]. The discussion
about eosinophils and development of AHR came to a cli-
max when the groups of Humbles and Lee reported about
the results of their studies in the same issue of the science
magazine. Humbles et al. used the Δdbl GATA mouse
which is completely deficient for the eosinophil lineage
due to deletion of a high affinity GATA site of the GATA-1
promotor in a mouse model of experimental asthma to
demonstrate that eosinophils are not obligatory for aller-
gen-induced lung dysfunction [26]. In contrast, Lee uti-
lized the transgenic PHIL mouse that is specifically devoid
of eosinophils, to show that these are required for devel-
opment of AHR [27].
Even though both studies seem to be contradictory regard-
ing the role of eosinophils within the development of
AHR, both studies linked eosinophils to the development
of airway remodelling. Whereas Lee et al. reported the lack
of goblet cell metaplasia in PHIL mice Humbles et al.
clearly demonstrated that eosinophil deficient animals
were protected from airway fibrosis and smooth muscle
cell hyperplasia. These findings receive further support
from studies that report about the profibrotic effects of
eosinophils on fibroblasts in vitro[28-30] and the results
concerning antagonization of CCR-3 that were produced
by Fulkerson et al. [31] and by our group.
Besides the fact that TH2 cells induce goblet cell hyperpla-
sia and increased mucus production in asthmatic patients
by secreting IL-13 [32], very little is known about the con-
tribution of T cells to airway remodelling. Few recent stud-
ies focussed on this special issue and presented data that
in fact suggest the participation of TH2 cells in the devel-
opment of airway fibrosis and smooth muscle hyperpla-
sia. Komai et al. investigated the effect of a neutralizing
anti-CD4 antibody in a mouse model of chronic experi-
mental asthma [33]. The i.p. administration of this anti-
body during the chronic OVA aerosol challenge did not
only result in diminished airway inflammation and
reduced amounts of TH2-type cytokines in broncho-alve-
olar lavage fluids, but also decreased goblet cell hyperpla-
sia and airway fibrosis. This was further accompanied by
the observation that neutralizing CD4 downsized the
level of TGF-β in BAL fluids as well. Additional experi-
ments from the same group focussed on the question
whether typical TH2-type cytokines such as IL-4 and IL-5
may contribute to airway remodelling. For this purpose
IL-4 deficient animals were sensitized to OVA and chron-
ically exposed to an OVA aerosol. Compared to wild type
animals, IL-4 deficient animals did not develop allergic
airway inflammation and did not reveal any signs of air-
way remodelling as indicated by lack of goblet cell hyper-
plasia and subepithelial fibrosis. Similar results could be
observed in animals that were deficient for the alpha
chain of the IL-5 receptor. In contrast, OVA-sensitized IL-
5 transgenic (tg) mice that systemically overexpress IL-5
showed even higher levels of TGF-β and enhanced subep-
ithelial fibrosis than wild type animals after chronic OVA
aerosol challenge [13].
Although all these studies reported about reduced airway
remodelling after abolishing CD4 positive T cells or TH2-
type cytokines one could argue that all these effects might
be indirect since these lowered effects were always associ-
ated with diminished airway eosinophilia. However, a
study by Ramos-Barbon gave evidence that TH2 cells can
directly induce airway remodelling [34]. In contrast to all
previously mentioned studies these experiments were car-
ried out in the rat, since this species is from an anatomical
point of view more suitable to mimic changes of the air-
way smooth muscle layer. In this study CD4 positive T
cells from OVA-sensitized rats, that were challenged
chronically with OVA aerosol and revealed signs of airway
remodelling including airway smooth muscle cell
(ASMC) hyperplasia, were adoptively transferred to naïve
rats. After OVA aerosol challenge these CD4 positive T
cells infiltrated the airway tissue and could be localized in
close contact to muscle cells of the airways and airway ves-
sels. This was further associated with increased airway
smooth muscle mass indicating ASMC hypertrophy. By
using immuno-histological staining methods Ramos-Bar-
bon et al. were able to clearly demonstrate that ASMCs
from adoptively transfered animals exhibited increased
proliferation and reduced apoptosis. All the data pre-
sented in this study support the idea that airway smooth
muscle remodelling, as an important feature of asthma, isJournal of Occupational Medicine and Toxicology 2008, 3(Suppl 1):S4 http://www.occup-med.com/content/3/S1/S4
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driven by antigen-specific T helper cells that require direct
myocyte-T cell contact.
Conclusion
Animal models of experimental asthma have elucidated
the central role of TH2 cells and their typical cytokines in
the acute inflammatory process resulting in the formation
of asthma. To answer the question whether these cells are
further involved in pathophysiological processes ulti-
mately leading to airway remodelling and chronification
of the disease improved models of chronic experimental
asthma that are able to reflect the chronic aspects of this
disease as close as possible had to be established. Recent
studies used such models to demonstrate that TH2 cells
play a critical role in asthma chronification especially in
airway remodelling as well. Therefore, these cells still rep-
resent promising target cells for therapeutic intervention
in asthmatic patients. After embryonic development the
pleiotropic transcription factor GATA-3 remains to be
expressed in bone marrow derived cells such as eosi-
nophils, basophils, mast cells and especially in T cells
[35,36]. During T helper cell development GATA-3
expression promotes TH2 responses through at least three
different mechanisms and therefore represents a crucial
event in T cell polarization [37-40]. Furthermore, overex-
pression of GATA-3 leads to increased airway remodelling
in a mouse model of chronic experimental asthma [41].
So due to its central role within the pathology of asthma
GATA-3 represents an interesting target for new anti-aller-
gic strategies, that might even be able to interfere with
processes that ultimately lead to airway remodelling.
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